vs
Side-by-side financial comparison of First Bancorp, Inc (FNLC) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
ARS Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($28.1M vs $25.8M, roughly 1.1× First Bancorp, Inc). First Bancorp, Inc runs the higher net margin — 39.4% vs -147.1%, a 186.5% gap on every dollar of revenue. On growth, First Bancorp, Inc posted the faster year-over-year revenue change (17.5% vs -67.6%).
Patriot Bank, N.A. (PNBK) is the bank holding company for Stamford, Connecticut-based Patriot Bank NA, and is traded on NASDAQ as PNBK.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
FNLC vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.8M | $28.1M |
| Net Profit | $10.2M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | 48.1% | -147.6% |
| Net Margin | 39.4% | -147.1% |
| Revenue YoY | 17.5% | -67.6% |
| Net Profit YoY | 39.7% | -182.8% |
| EPS (diluted) | $0.91 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.8M | $28.1M | ||
| Q3 25 | $24.5M | $32.5M | ||
| Q2 25 | $22.5M | $15.7M | ||
| Q1 25 | $21.8M | $8.0M | ||
| Q4 24 | $22.0M | $86.6M | ||
| Q3 24 | $20.5M | $2.1M | ||
| Q2 24 | $19.2M | $500.0K | ||
| Q1 24 | $18.5M | $0 |
| Q4 25 | $10.2M | $-41.3M | ||
| Q3 25 | $9.1M | $-51.2M | ||
| Q2 25 | $8.1M | $-44.9M | ||
| Q1 25 | $7.1M | $-33.9M | ||
| Q4 24 | $7.3M | $49.9M | ||
| Q3 24 | $7.6M | $-19.1M | ||
| Q2 24 | $6.2M | $-12.5M | ||
| Q1 24 | $6.0M | $-10.3M |
| Q4 25 | 48.1% | -147.6% | ||
| Q3 25 | 45.2% | -163.7% | ||
| Q2 25 | 43.7% | -302.9% | ||
| Q1 25 | 39.3% | -466.3% | ||
| Q4 24 | 39.5% | 54.5% | ||
| Q3 24 | 44.6% | -1051.6% | ||
| Q2 24 | 38.8% | -3068.0% | ||
| Q1 24 | 39.3% | — |
| Q4 25 | 39.4% | -147.1% | ||
| Q3 25 | 37.0% | -157.4% | ||
| Q2 25 | 35.8% | -285.6% | ||
| Q1 25 | 32.5% | -425.7% | ||
| Q4 24 | 33.1% | 57.7% | ||
| Q3 24 | 36.9% | -925.0% | ||
| Q2 24 | 32.1% | -2503.2% | ||
| Q1 24 | 32.5% | — |
| Q4 25 | $0.91 | $-0.41 | ||
| Q3 25 | $0.81 | $-0.52 | ||
| Q2 25 | $0.72 | $-0.46 | ||
| Q1 25 | $0.63 | $-0.35 | ||
| Q4 24 | $0.66 | $0.52 | ||
| Q3 24 | $0.68 | $-0.20 | ||
| Q2 24 | $0.55 | $-0.13 | ||
| Q1 24 | $0.54 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.0M |
| Total DebtLower is stronger | $95.5M | $96.4M |
| Stockholders' EquityBook value | $283.1M | $114.3M |
| Total Assets | $3.2B | $327.7M |
| Debt / EquityLower = less leverage | 0.34× | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $245.0M | ||
| Q3 25 | — | $288.2M | ||
| Q2 25 | — | $240.1M | ||
| Q1 25 | — | $275.7M | ||
| Q4 24 | — | $314.0M | ||
| Q3 24 | — | $204.6M | ||
| Q2 24 | — | $218.7M | ||
| Q1 24 | — | $223.6M |
| Q4 25 | $95.5M | $96.4M | ||
| Q3 25 | $95.5M | $96.2M | ||
| Q2 25 | $95.0M | — | ||
| Q1 25 | $70.0M | — | ||
| Q4 24 | $95.0M | $0 | ||
| Q3 24 | $95.0M | — | ||
| Q2 24 | $70.0M | — | ||
| Q1 24 | $70.0M | — |
| Q4 25 | $283.1M | $114.3M | ||
| Q3 25 | $274.6M | $147.7M | ||
| Q2 25 | $265.5M | $192.3M | ||
| Q1 25 | $259.7M | $229.0M | ||
| Q4 24 | $252.5M | $256.8M | ||
| Q3 24 | $256.8M | $201.0M | ||
| Q2 24 | $244.7M | $215.2M | ||
| Q1 24 | $242.6M | $223.9M |
| Q4 25 | $3.2B | $327.7M | ||
| Q3 25 | $3.2B | $372.8M | ||
| Q2 25 | $3.2B | $313.5M | ||
| Q1 25 | $3.2B | $327.3M | ||
| Q4 24 | $3.2B | $351.2M | ||
| Q3 24 | $3.1B | $217.6M | ||
| Q2 24 | $3.1B | $222.0M | ||
| Q1 24 | $3.0B | $227.6M |
| Q4 25 | 0.34× | 0.84× | ||
| Q3 25 | 0.35× | 0.65× | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | 0.00× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.29× | — | ||
| Q1 24 | 0.29× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $37.8M | $-43.5M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 133.9% | — |
| Capex IntensityCapex / Revenue | 12.5% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $55.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.8M | $-43.5M | ||
| Q3 25 | $12.9M | $-47.0M | ||
| Q2 25 | $7.4M | $-39.6M | ||
| Q1 25 | $2.2M | $-40.7M | ||
| Q4 24 | $26.0M | $42.0M | ||
| Q3 24 | $9.8M | $-14.5M | ||
| Q2 24 | $6.4M | $-7.3M | ||
| Q1 24 | $-1.5M | $-6.7M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $12.6M | $-47.2M | ||
| Q2 25 | $7.2M | $-39.6M | ||
| Q1 25 | $828.0K | $-40.8M | ||
| Q4 24 | $24.6M | $41.7M | ||
| Q3 24 | $9.6M | $-14.6M | ||
| Q2 24 | $6.3M | $-7.3M | ||
| Q1 24 | $-1.8M | $-6.8M |
| Q4 25 | 133.9% | — | ||
| Q3 25 | 51.4% | -145.4% | ||
| Q2 25 | 32.1% | -252.2% | ||
| Q1 25 | 3.8% | -512.1% | ||
| Q4 24 | 111.7% | 48.2% | ||
| Q3 24 | 47.0% | -706.3% | ||
| Q2 24 | 32.9% | -1463.4% | ||
| Q1 24 | -9.8% | — |
| Q4 25 | 12.5% | 0.0% | ||
| Q3 25 | 1.2% | 0.6% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 6.2% | 1.1% | ||
| Q4 24 | 6.7% | 0.3% | ||
| Q3 24 | 0.5% | 6.8% | ||
| Q2 24 | 0.3% | 7.6% | ||
| Q1 24 | 1.8% | — |
| Q4 25 | 3.72× | — | ||
| Q3 25 | 1.42× | — | ||
| Q2 25 | 0.91× | — | ||
| Q1 25 | 0.31× | — | ||
| Q4 24 | 3.58× | 0.84× | ||
| Q3 24 | 1.29× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | -0.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNLC
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
